CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
17mm MDT-2215 aortic valve bioprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02686814
NCT02686814N/ACompleted

A Multi-center, Non-randomized Trial to Determine the Safety and Effectiveness of the 17mm MDT-2215 Aortic Valve Bioprosthesis in Patients With Aortic Valve Disease

Medtronic Cardiac Surgery·interventional·Posted Feb 22, 2016·Updated Apr 12, 2024

In Brief

A clinical study evaluating 17mm MDT-2215 aortic valve bioprosthesis for Aortic Stenosis. Completed, enrolled 25 participants across 10 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of the 17mm MDT-2215 aortic valve bioprosthesis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Stenosis
CountriesJapan
CollaboratorsMedtronic

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 22, 2016
Enrollment StartMar 1, 2016
Primary CompletionMay 1, 2018
Study CompletionJul 15, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.4 years ago

Interventions

17mm MDT-2215 aortic valve bioprosthesisdevice